Details
Title
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
Author
Kost, Sara E. F. 1 ; Saleh, Ali 2 ; Yuan, Shek H. 2 ; Kuzio, Bozena 2 ; Gibson, Spencer B. 3 ; Yang, Lin 4 ; Banerji, Versha 5 ; Johnston, James B. 6 ; Katyal, Sachin 2
1 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170)
2 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
3 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Alberta, Department of Oncology, Edmonton, Canada (GRID:grid.17089.37) (ISNI:0000 0001 2190 316X)
4 University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
5 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609); University of Manitoba, Department of Biochemistry and Medical Genetics Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
6 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
1 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170)
2 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
3 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Alberta, Department of Oncology, Edmonton, Canada (GRID:grid.17089.37) (ISNI:0000 0001 2190 316X)
4 University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
5 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609); University of Manitoba, Department of Biochemistry and Medical Genetics Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
6 CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
Pages
20
Publication year
2023
Publication date
Dec 2023
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2770187624
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.